LINVESTA-EMP 5/25 LINAGLIPTIN/EMPAGLIFLOZIN 25MG TABS 28’S

Linvesta-Emp 5/25 is a combination medication containing Linagliptin and Empagliflozin, primarily used for the management of type 2 diabetes mellitus. Linagliptin is a DPP-4 inhibitor that helps to increase insulin secretion and decrease glucagon levels in the blood, thereby lowering blood sugar levels. Empagliflozin, on the other hand, is an SGLT2 inhibitor that works by preventing the reabsorption of glucose in the kidneys, promoting its excretion through urine, which also aids in reducing blood sugar levels.

This combination not only helps in controlling blood glucose levels but also offers additional benefits such as weight loss and potential cardiovascular protection. Linvesta-Emp 5/25 is typically prescribed for patients who require more than one medication to achieve optimal glycemic control. It is available in tablet form, with each pack containing 28 tablets, making it convenient for daily use. Always consult a healthcare professional before starting any new medication.